Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
– Profiling of IL-38 mRNA in over 60 cancer types revealed notably high frequency (60-80%) of IL-38 expression in select solid tumor sub-types of high unmet clinical need –
– Collaboration with Fox Chase Cancer Center to directly confirm IL-38 protein expression in patients –
– Anticipated IND filing in 2H 2022 –
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
– Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters –
– IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional testing underway –
Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter
Strengthened executive team with appointment of Fred Driscoll as CFO
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap
Scripps Health and UT Health San Antonio purchase Oncora’s software to improve physician documentation and enhance personalized cancer care